Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Fox

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Annals of Hematology|August 30, 2022
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia VeraAna Triguero, Alexandra Pedraza, Manuel Pérez-Encinas, et al.
Blood Advances|May 29, 2024
PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMTJuan Montoro, Maud Ngoya, Alexander Kulagin, et al.
Bone Marrow Transplantation|February 2, 2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMTGiorgia Battipaglia, Katya Mauff, Lotus Wendel, et al.
Annals of Hematology|February 4, 2018
Prognostic risk models for transplant decision-making in myelofibrosisJuan-Carlos Hernández-Boluda, Arturo Pereira, Juan-Gonzalo Correa, et al.
Blood Advances|November 29, 2021
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignanciesMoraima Jiménez, Elisa Roldán, Candela Fernández-Naval, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
European Journal of Haematology|December 4, 2020
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative studyManuel M Pérez Encinas, Marta Sobas, María Teresa Gómez-Casares, et al.
British Journal of Haematology|August 4, 2020
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential ThrombocythaemiaAlberto Alvarez-Larrán, Anna Angona, Marcio Andrade-Campos, et al.
Transplantation and Cellular Therapy|March 7, 2026
Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapyRebeca Bailén, Felipe Peña-Muñoz, Arancha Bermúdez, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Annals of Hematology|August 30, 2022
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia VeraAna Triguero, Alexandra Pedraza, Manuel Pérez-Encinas, et al.
Blood Advances|May 29, 2024
PTCy vs CNI-based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMTJuan Montoro, Maud Ngoya, Alexander Kulagin, et al.
Bone Marrow Transplantation|February 2, 2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMTGiorgia Battipaglia, Katya Mauff, Lotus Wendel, et al.
Annals of Hematology|February 4, 2018
Prognostic risk models for transplant decision-making in myelofibrosisJuan-Carlos Hernández-Boluda, Arturo Pereira, Juan-Gonzalo Correa, et al.
Blood Advances|November 29, 2021
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignanciesMoraima Jiménez, Elisa Roldán, Candela Fernández-Naval, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
European Journal of Haematology|December 4, 2020
The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative studyManuel M Pérez Encinas, Marta Sobas, María Teresa Gómez-Casares, et al.
British Journal of Haematology|August 4, 2020
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential ThrombocythaemiaAlberto Alvarez-Larrán, Anna Angona, Marcio Andrade-Campos, et al.
Transplantation and Cellular Therapy|March 7, 2026
Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapyRebeca Bailén, Felipe Peña-Muñoz, Arancha Bermúdez, et al.
Pageof 9